Rep. Doggett: Seeking Answers From Gilead on Remdesivir
May 05, 2020
May 05, 2020
WASHINGTON, May 5 -- Rep. Lloyd Doggett, D-Texas, issued the following news release:
U.S. Representative Lloyd Doggett (D-TX), Chairman of the House Ways and Means Health Subcommittee, led Members in urging Gilead CEO Daniel O'Day to detail the company's plans for remdesivir, including securing and scaling up the supply chain, complete disclosures of taxpayer investment in the development of the drug, and purchase and pricing arrangements. As remdesivir--which has been developed wit . . .
U.S. Representative Lloyd Doggett (D-TX), Chairman of the House Ways and Means Health Subcommittee, led Members in urging Gilead CEO Daniel O'Day to detail the company's plans for remdesivir, including securing and scaling up the supply chain, complete disclosures of taxpayer investment in the development of the drug, and purchase and pricing arrangements. As remdesivir--which has been developed wit . . .